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At least four hantavirus species cause disease with prominent renal involvement-hemorrhagic fever with renal syndrome (HFRS); and several
hantavirus strains cause disease with significant pulmonary involvement-hantavirus pulmonary syndrome (HPS). The most prevalent and lethal
hantaviruses associated with HFRS and HPS are Hantaan virus (HTNV) and Andes virus (ANDV), respectively. Here, we constructed a DNA
vaccine plasmid (pWRG/HA-M) that contains both the HTNV and ANDV M gene segments. Rhesus macaques vaccinated with pWRG/HA-M
produced antibodies that bound the M gene products (i.e., G1 and G2 glycoproteins), and neutralized both HTNV and ANDV. Neutralizing
antibody titers elicited by the dual-immunogen pWRG/HA-M, or single-immunogen plasmids expressing only the HTNV or ANDV
glycoproteins, increased rapidly to high levels after a booster vaccination administered 1–2 years after the initial vaccination series. Memory
responses elicited by this long-range boost exhibited an increased breadth of cross-neutralizing activity relative to the primary response. This is the
first time that hantavirus M gene-based DNA vaccines have been shown to elicit a potent memory response, and to elicit antibody responses that
neutralize viruses that cause both HFRS and HPS.
Published by Elsevier Inc.Keywords: Hantavirus; DNA vaccine; Hantaan virus; Andes virus; Neutralizing antibodiesIntroduction
Hantaviruses are rodent-borne viruses that cause hemor-
rhagic fever in humans. Different hantaviruses are associated
with different disease syndromes with varying degrees of
severity. There are at least four hantaviruses associated with
hemorrhagic fever with renal syndrome: Hantaan virus
(HTNV), Seoul virus (SEOV), Dobrova virus (DOBV), and
Puumala virus (PUUV). The most prevalent and lethal HFRS-
associated hantavirus is HTNV (>100,000 cases per year,
mostly in Asia) with a case-fatality rate of 10–15%. Several
hantaviruses are associated with hantavirus pulmonary syn-
drome (HPS) including Andes virus (ANDV), Sin Nombre
virus (SNV), and Black Creek Canal virus (BCCV). There
have been over 1900 cases of HPS in the Americas between
1993 and 2004 and ANDV (found in Argentina and Chile) is
believed to be the etiologic agent for approximately half of0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.11.035
* Corresponding author. Fax: +1 301 619 2439.
E-mail address: Jay.Hooper@amedd.army.mil (J.W. Hooper).these cases (PAHO, 2004; Tischler et al., 2005). There are no
vaccines or specific antiviral drugs licensed by the Food and
Drug Administration to treat or prevent HFRS or HPS.
Hantaviruses, family Bunyaviridae, have a genome consist-
ing of three segments of negative-sense RNA. The large (L),
small (S), and medium (M) segments encode the RNA-
dependent RNA polymerase, nucleocapsid, and surface glyco-
proteins (G1 and G2), respectively (Schmaljohn and Hooper,
2001). We previously demonstrated that M genome segment-
based DNA vaccines expressing either the SEOV, HTNV, or
ANDV G1 and G2 glycoproteins elicit high-titer neutralizing
antibodies in nonhuman primates (Custer et al., 2003; Hooper
et al., 1999, 2001a). Here, we report the construction and
testing of a DNA vaccine plasmid (pWRG/HA-M) that
contains both the HTNV and ANDV M genome segments.
This DNA vaccine was capable of eliciting antibodies that
cross-neutralized both HFRS and HPS hantaviruses after the
initial vaccination series. Interestingly, a booster vaccination
administered >1 year after the initial series increased the cross-
neutralizing antibody response. This long-range boost effect on
cross-neutralizing antibody was also observed in nonhuman6) 208 – 216
www.e
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segment-based DNA vaccines.
Results
Construction of a DNA vaccine plasmid expressing both the
HTNV and ANDV G1 and G2 glycoproteins
A plasmid containing the M genome segments of both
HTNV and ANDV was constructed by using pWRG/AND-M
(Custer et al., 2003) as template and PCR-amplifying the
ANDV M genome segment, flanked by the CMV promoter/
intron A at the 5V end and polyadenylation signal at the 3V end.
This cassette was inserted into the XbaI site downstream of the
HTNV M genome segment contained in pWRG/HTN-M(x)
(Fig. 1A). The resulting plasmid, pWRG/HA-M, was tested for
expression of the glycoproteins of HTNVand ANDV by RIPA.Fig. 1. Construction and expression of pWRG/HA-M DNA vaccine plasmid.
The pWRG/HA-M DNA vaccine plasmid was constructed by PCR-amplifying
a region of pWRG/AND-M including the CMV promoter, intron A, AND-M
genome segment, and bovine growth hormone polyadenylation signal. This
fragment was cloned into the pWRG/HTN-M plasmid at the XbaI site (A).
Expression of both AND-M and HTN-M from pWRG/HA-M was confirmed
by RIPA using radiolabeled lysates from COS-7 cells transfected with pWRG/
HTN-M (upper panel) or pWRG/HA-M (lower panel) and using HTN-M- and
AND-M-specific sera (B). HMAF generated to HTNV detects both G1 and G2,
while MAb 6D4 detects HTN-G1 and MAb-HC02 detects HTN-G2. HPS
convalescent phase sera detect ANDV G1 and G2. Normal human serum is
included as a negative control.The G1 and G2 glycoproteins of both viruses were expressed
from pWRG/HA-M (Fig. 1B).
pWRG/HA-M elicits HFRS and HPS hantavirus neutralizing
antibodies in NHPs
To test the immunogenicity of the candidate single-plasmid
HFRS/HPSDNAvaccine, two rhesusmacaqueswere vaccinated
with pWRG/HA-M four times at 3-week intervals using a gene
gun. Sera collected 3 weeks after the fourth vaccination were
tested for neutralizing antibodies by PRNT. Serum from NHPs
vaccinated with pWRG/HA-M neutralized both ANDV and
HTNV (Figs. 2A–B and Table 1). This is the first description of
any candidate experimental hantavirus vaccine eliciting neutral-
izing antibodies against both HFRS and HPS hantaviruses.
To determine the breadth of the neutralizing antibody
response, we tested the capacity of the serum to cross-
neutralize two North American HPS-associated hantaviruses
(SNV and BCCV) and the remaining three HFRS-associated
hantaviruses (SEOV, DOBV, and PUUV) (Table 1). We found
that each NHP exhibited a different pattern of cross-neutraliz-
ing activity. Serum from NHP CAA neutralized three of the
seven viruses tested and serum from NHP HJV neutralized five
of the seven. Neither NHP produced antibodies that neutralized
SEOV or PUUV.
HFRS, HPS, and HFRS/HPS DNA vaccines elicited antibody
responses that were readily boosted 1 to 2 years after the initial
vaccination series
We monitored the levels of neutralizing antibodies in serum
fromNHPs vaccinated with pWRG/HA-M and observed that the
level of both HTNV and ANDV neutralizing antibodies fell
below detection 5months after the fourth vaccination (Figs. 2A–
B). In earlier studies in NHPs, we had reported that the HFRS
DNA vaccine (pWRG/HTN-M[x]) and HPS DNA vaccine
(pWRG/AND-M) elicited high-titer neutralizing antibodies that
were still detectable up to 5 months after the initial vaccination
series (Custer et al., 2003; Hooper et al., 2001a) (Figs. 2C–D).
To further investigate the duration of immunity elicited by
pWRG/HTN-M(x) or pWRG/AND-M, we extended the study
and found that homologous neutralizing antibody responses
were still detected more than 2 years after the initial vaccination
series (Figs. 2C–D). Together, these data indicated that DNA
vaccine plasmids containing single hantavirus M genes were
capable of eliciting homologous neutralizing antibody titers that
were more durable than a single plasmid DNA vaccine contain-
ing a combination of two hantavirus M genes.
To determine if the immune responses generated with any of
these three DNA vaccines could be readily recalled years after
the initial vaccination, we administered a single booster
vaccination 1–2 years after the initial vaccination series. For
each animal, the booster vaccination consisted of the same
DNA vaccine used in the initial series of vaccinations. In all
cases, a dramatic increase in neutralizing antibody titers was
observed within 11 days after the long-range boost (Figs. 2A–
D). In most cases, the neutralizing antibody titers rose to
Fig. 2. Immunogenicity of hantavirus DNA vaccines in nonhuman primates. Rhesus macaques were vaccinated with pWRG/HA-M (A and B), pWRG/AND-M (C), or pWRG/HTN-M (D). Neutralizing antibody
responses were determined by PRNT after each vaccination and at the indicated weeks. The PRNT50 of pWRG/AND-M-vaccinated NHPs to ANDV is shown in panel C. Monkey CH69 was vaccinated on weeks 0, 3,
6, and 12 while monkey 90BD25 was vaccinated on weeks 0, 3, 6, and 9. A long-range booster vaccination was administered at weeks 110 and 85, respectively. NHPs vaccinated with pWRG/HTN-M at weeks 0, 3, 6,
and 128 were tested for NAb to HTNV (D). NHP vaccinated with pWRG/HA-M at weeks 0, 3, 6, 9, and 85 was tested for NAb against both ANDV (A) and HTNV (B).
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Table 1
pWRG/HA-M elicits neutralizing antibodies in NHP against both HFRS and HPS hantavirusesa
Vaccine Monkey ID PRNT50
b
HPSc HFRSd
ANDV SNV BCCV HTNV SEOV DOBV PUUV
pWRG/HA-M CAA 320 <e < 320 < 40 <
HJV 640 20 20 640 < 20 <
pWRG/AND-M CH69 20,480* 640* 2560* <* < < <
90BD25 10,240* 1280 < <* < < <
pWRG/HTN-M(x) CH64 <* <* <* 20,480* 160 1280 <
CH85 <* <* <* 20,480* 40 10,240 <
CH28 < < <* 2560* <* 320* <*
CH02 < < <* 10,240* <* 320* <*
a Serum was collected 3 weeks after the final vaccination in the initial series.
b Reciprocal of highest dilution neutralizing 50% of the plaques as measured by plaque reduction neutralization test (PRNT) for particular viruses (as indicated).
c Viruses associated with hantavirus pulmonary syndrome (HPS).
d Viruses associated with hemorrhagic fever with renal syndrome (HFRS).
e Less than symbol (<) indicates titer was below detection, <20.
* Data indicated with an asterisk are previously published from other studies and used here as historical data.
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vaccination series. These data demonstrated that all three of
the hantavirus DNA vaccines elicit potent memory responses.
RIPA performed using pre- and postboost serum from an
NHP vaccinated with pWRG/AND-M or pWRG/HA-MFig. 3. The immune response to G1 and G2 of DNA vaccines is boostable years
after the initial vaccination. The ability to boost G1 and G2 responses in NHP
vaccinated with pWRG/AND-M or pWRG/HA-M was determined by
collecting preboost (pre) and postboost (post) sera and testing by RIPA for
G1- and G2-specific antibodies. Radiolabeled lysates from COS-7 cells
transfected with AND-M (A) or HTN-M (B) were reacted with sera of
pWRG/AND-M-vaccinated NHP (CH69 and 90BD25) or sera of pWRG/HA-
M-vaccinated NHP (CAA and HJV).indicated that antibodies to both G1 and G2 of ANDV were
detected (Fig. 3). The serum from NHPs vaccinated with
pWRG/HA-M was more reactive with the ANDV G1 and G2
than the HTNV G1 and G2 (Fig. 3). These biochemical data
correlated with the immunogenicity data whereby the ANDV
neutralizing antibody titers were 4- to 8-fold greater than
HTNV neutralizing antibody titers.
Increased capacity to cross-neutralize after long-range booster
vaccination
The preboost serum from both NHPs vaccinated with pWRG/
AND-M contained detectable levels of G1- and G2-specific
antibodies (Fig. 3). This is impressive because one of the NHPs,
CH69, was vaccinated 2 years earlier. This same animal was also
interesting because its postboost serum immunoprecipitated
HTNV G2 (Fig. 3). This was unexpected because serum
collected from CH69 3 weeks after the initial vaccination series
did not immunoprecipitate HTNV G1 or G2 and did not cross-
neutralize HTNV (Custer et al., 2003). This finding suggested
that a booster vaccination might result in a qualitatively different
antibody response (e.g., greater avidity) with more broadly
cross-neutralizing activity. To test this possibility, we performed
cross-neutralization PRNT on serum collected after the long-
range booster vaccination. The level of cross-neutralizing
activity went up in the serum from five of the six NHPs that
received long-range booster vaccinations (Table 2). Even NHPs
that were vaccinated with the HFRS or HPS DNA vaccine
produced antibodies that cross-neutralized HPS- or HFRS-
associated hantaviruses, respectively. In fact, the level of cross-
neutralizing activity in the NHPs vaccinated with the HFRS or
HPS DNAwas similar to that observed in the NHPs vaccinated
with the dual HFRS/HPS DNA vaccine.
To determine how durable the neutralizing antibody
response was after the long-range boost, NHPs were bled 82
weeks after the booster vaccination and PRNT was performed.
The memory response elicited by the long-range boost was
quite impressive as evidenced by the ability of sera from the
Table 2
Cross-neutralizing activity after long-range booster vaccination
Vaccine Monkey ID Duration between prime and boosta PRNT50
b
HPSc HFRSd
ANDV SNV BCCV HTNV SEOV DOBV PUUV
pWRG/HA-M CAA 76 1280 <e 80 160 < < <
HJV 76 5120 160 320 640 320 640 20
pWRG/AND-M CH69 98 20,480 640 2560 40 40 640 20
90BD25 76 40,960 1280 320 < < 40 <
pWRG/HTN-M(x) CH28 119 20 80 80 20,480 2560 2560 <
CH02 119 < < 80 40,960 640 2560 <
a Duration between prime and boost is defined as the number of weeks between the final vaccination in the initial series and the long-range boost.
b Reciprocal of highest dilution neutralizing 50% of the plaques as measured by plaque reduction neutralization test (PRNT) for particular viruses (as indicated).
c Viruses associated with hantavirus pulmonary syndrome (HPS).
d Viruses associated with hemorrhagic fever with renal syndrome (HFRS).
e Less than symbol (<) indicates titer was below detection, <20.
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tralize virus (Figs. 2A–D). Sera from the pWRG/HA-M-
vaccinated NHPs was able to neutralize ANDV, BCCV, and
HTNV while sera from the pWRG/AND-M-vaccinated NHPs
neutralized only the HPS associated viruses, albeit with
exceptionally high titers (Table 3).
pWRG/HA-M does not elicit neutralizing antibodies in
hamsters
We previously reported that vaccination with the SEOV or
HTNV M segment-based DNA vaccine but not ANDV M
segment-based DNA vaccine elicited neutralizing antibodies in
Syrian hamsters (Custer et al., 2003). The mechanism
underlying the species difference in pWRG/AND-M immuno-
genicity is not known. To rule out the possibility that a
technical error could account for the absence of detectable
immunity in hamsters, we performed an experiment where
three cynomolgus macaques and eight Syrian hamsters were
vaccinated on the same days with pWRG/AND-M gene gun
cartridges from the same lot. Animals were vaccinated on
weeks 0, 2, 3, and 8. Serum collected from all three
cynomolgus macaques contained ANDV neutralizing antibo-
dies: GMT50 = 40, 640, and 1280. In contrast, neutralizing
antibodies were not detected in any of the eight vaccinatedTable 3
Neutralizing antibody memory response elicited after a long-range booster vaccina
Vaccine Monkey ID Weeks after boost until bleeda PRNT
HPSc
ANDV
pWRG/HA-M CAA 82 20
HJV 82 40
pWRG/AND-M CH69 82 10,240
90BD25 82 1280
a Duration between boost and bleed is defined as the number of weeks between
b Reciprocal of highest dilution neutralizing 50% of the plaques as measured by p
c Viruses associated with hantavirus pulmonary syndrome (HPS).
d Viruses associated with hemorrhagic fever with renal syndrome (HFRS).
e Less than symbol (<) indicates titer was below detection, <20.hamsters (data not shown). These data demonstrate that the
pWRG/AND-M DNA vaccine administered by gene gun was
immunogenic in a second species of macaque (i.e., cynomolgus
macaque), and confirms that this plasmid was not immuno-
genic in Syrian hamsters.
We inoculated hamsters with the pWRG/HA-M vaccine to
determine if it was capable of eliciting HTNV and/or ANDV
neutralizing antibodies in that species. Eight hamsters were
vaccinated with pWRG/HA-M three times at 3-week intervals
using a gene gun. Three weeks after the third vaccination,
serum was collected and tested for HTNV or ANDV
neutralizing antibodies. No HTNV or ANDV neutralizing
antibodies were detected in any hamsters (data not shown).
In contrast, eight positive control hamsters vaccinated with
pWRG/HTN-M(x) developed HTNV neutralizing antibodies
(PRNT50 GMT = 226; range 20–1280). The hamsters
vaccinated with pWRG/HA-M and a group of unvaccinated
negative control hamsters were challenged with HTNV. In both
groups, seven of eight hamsters were not protected from
infection because they demonstrated serological evidence of
infection. Thus, the ANDV M genome segment contained in
pWRG/HA-M was not only nonimmunogenic in hamsters
(when delivered by gene gun), but it also exerted a dominant-
negative effect on the immunogenicity of the HTNV M
genome segment component of the vaccine.tion
50
b
HFRSd
SNV BCCV HTNV SEOV DOBV PUUV
<e < 20 < < <
< 20 20 < < <
160 320 < < < <
160 20 < < < <
the long-range booster vaccination and the final bleed.
laque reduction neutralization test (PRNT) for particular viruses (as indicated).
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We previously reported that candidate HFRS and HPS
DNA vaccines administered by gene gun elicit high-titer
neutralizing antibodies in NHPs (Custer et al., 2003; Hooper et
al., 2001a). Thus, a DNA vaccine comprised of these two
plasmids (expressing the HTNV and ANDV M genes,
respectively) could be considered a candidate HFRS/HPS
vaccine. Here, we have explored an alternative strategy
whereby dual hantavirus M genes were combined into a
single plasmid. One advantage of this approach is that it
simplifies downstream production processes and reduces costs
because there are fewer drug substances (plasmids) to
manufacture and characterize. The use of a bi- or multi-
immunogen plasmid can alleviate some of the drawbacks
associated with a multiplasmid approach provided that there
are sufficient immune responses elicited against each of the
target immunogens. Previous reports suggest that it is possible
to actually improve immunogenicity by using dual-immuno-
gen constructs as compared to administration of separate
plasmids. For example Song et al. (2005) reported the
generation of a DNA vaccine plasmid expressing measles
virus hemagglutinin (MV-H) and fusion (MV-F) proteins. A
decrease in MV-specific serum PRNT titers and avidity in
mice vaccinated with dual-immunogen constructs was ob-
served; however, the mice showed increases in IFN-gamma
producing MV-specific splenocytes compared to mice vacci-
nated with MV-H or MV-F on separate plasmids. Several
groups have used a bicistronic DNA vaccine approach to
combine an immunogen-of-interest with cytokines or co-
stimulatory molecules (e.g., interleukin-18 or GM-CSF) on
the same plasmid (Chang et al., 2004; Lee et al., 1998). In
those studies, immunogenicity to the vaccine immunogen-of-
interest was improved relative to co-administration of separate
plasmids. To date, the use of dual-immunogen plasmids has
only been used to improve the immunogenicity of vaccines
against single agents (Song et al., 2005). pWRG/HA-M is the
first multiagent DNA vaccine plasmid, to our knowledge, that
expresses target genes from different virus species (i.e., HTNV
and ANDV).
Immunogenicity of pWRG/HA-M
NHPs vaccinated with pWRG/HA-M developed antibody
responses that neutralized both HTNV and ANDV; however,
the endpoint titers were several-fold lower than those achieved
with plasmids expressing only the HTNV or ANDV glycopro-
teins (Fig. 2 and Table 1). Nevertheless, the titers elicited by
pWRG/HA-M were respectable, especially in light of the fact
that the titers of neutralizing antibody generated by the
hantavirus M gene-based DNA vaccines pWRG/HTN-M(x)
and pWRG/AND-M (as high as PRNT50 = 40,960) were
among the highest levels of neutralizing antibodies reported for
any DNA vaccine to any viral antigen delivered to NHPs by
gene gun. These high-titer antibody responses, which are
similar to those produced in persons who survive HPS using
the same assay (unpublished data), demonstrate that potentneutralizing antibody responses can be achieved using a DNA
vaccine approach that requires neither adjuvant nor protein
boosts.
Duration of immunity
The neutralizing antibody response elicited by the dual-
immunogen DNA vaccine in this study was less durable than
that elicited by the single-immunogen vaccines. Two months
after the initial vaccination series with pWRG/HA-M, neutral-
izing antibodies against both HTNVand ANDV were detected;
however, at the next time point (3 months later), neutralizing
antibody levels were below detection. In contrast, the single-
immunogen vaccines elicited neutralizing antibody responses
that were still detectable 1–2 years after the initial vaccination
series (Figs. 2C–D). In all of the NHPs in Fig. 2, there was an
approximately 8- to 64-fold reduction in neutralizing antibody
titers during the first 6 months after the first vaccination. A
>16-fold reduction in antibodies would result in a PRNT titer
below detection for the pWRG/HA-M-vaccinated NHPs
because their peak titers were between 320 and 640 after the
initial vaccination series. Thus, the reduced duration of
detectable levels of antibody in the serum of NHPs vaccinated
with pWRG/HA-M was likely related to the reduced potency of
the initial response.
Long-range boost
Perhaps one of the most significant aspects of this study is
the finding that a single DNA vaccine booster vaccination 1–2
years after the initial series results in a rapid and potent rise in
levels of neutralizing antibodies. In most cases, the titers
achieved after this long-range boost were greater than the peak
titers after the initial vaccination series. This rapid recall of
neutralizing antibodies was detected in all eight NHPs that
received a booster vaccination. Unlike the initial pWRG/HA-M
series, the capacity of the sera to neutralize after the long-range
boost did not drop below detection after more than 1.5 years.
Longevity of memory response has also been reported after
DNA vaccination (via gene gun) of NHPs with a plasmid
encoding the rabies virus glycoprotein. In this study, neutral-
izing antibodies could be detected up to 588 days after the
initial vaccination (Lodmell et al., 2002).
The rapid recall response observed after long-range booster
vaccination could play a role in the efficacy of the vaccine. We
speculate that if a vaccinated person with a waning neutralizing
antibody response was exposed to a hantavirus, then the
resulting infection would trigger the same rapid rise in
neutralizing antibodies observed in NHPs that received a
long-range booster vaccination. If this were true, then these
neutralizing antibodies would rise to protective levels before
the virus could proceed through the 1–2 week hantavirus
incubation period. Bharadwaj et al. reported a correlation
between the level of neutralizing antibodies at the time of
hospital admission and severity of disease. Patients with higher
levels of neutralizing antibodies developed mild disease
whereas patients with lower levels of neutralizing antibodies
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strated that hamsters challenged with a lethal dose of ANDV
were protected against disease if injected with ANDV
neutralizing antibodies (produced in NHPs vaccinated with
pWRG/AND-M) up to 5 days after challenge (Custer et al.,
2003). These findings support the concept that maintenance of
high-titer neutralizing antibodies might not be necessary to
confer protection as long as a rapid recall of a neutralizing
antibody response occurs upon hantavirus exposure.
Cross-reactivity
One of our main goals is to develop a vaccine that protects
against multiple hantaviruses. Hence, we are interested in
evaluating the capacity of candidate vaccines to cross-
neutralizing (and presumably cross-protect) heterologous
hantaviruses. Convalescent sera from HFRS and HPS patients
have demonstrated a variable capacity to cross-neutralize
heterologous hantaviruses (Chu et al., 1995). In addition,
numerous reports on the evaluation of experimental HFRS
vaccines have described varying degrees of cross-neutralizing
antibody responses against HFRS-associated viruses (Hooper
and Li, 2001). In our previous studies, pWRG/HTN-M(x)
elicited antibodies that could neutralize three of the four HFRS
hantaviruses (i.e., HTNV, SEOV, DOBV), but not PUUV or
any of the HPS hantaviruses tested (Custer et al., 2003;
Hooper et al., 2001a). Conversely, pWRG/AND-M elicited
antibodies that could neutralize other HPS hantaviruses, but
not HFRS hantaviruses (Custer et al., 2003). Here, the NHPs
vaccinated with pWRG/HA-M developed neutralizing anti-
body responses against both HPS and HFRS hantaviruses after
the 4th vaccination. This is the first time any vaccine has
elicited neutralizing antibodies against both HFRS and HPS
hantaviruses. Interestingly, the capacity of not only pWRG/
HA-M but also pWRG/HTN-M(x) and pWRG/AND-M to
cross-neutralize heterologous hantaviruses increased after the
long-range booster vaccination. In fact, after the long-range
boost, two NHPs (HJV vaccinated with pWRG/HA-M and
CH69 vaccinated with pWRG/AND-M) developed antibodies
that neutralized all seven of the HPS and HFRS hantaviruses
in our panel. This finding indicates that a long-range booster
vaccination not only extends the duration of protective
immunity, but also might increase the breadth of cross-
protective immunity to include known and unknown hanta-
viruses that cause disease in humans. We speculate that the
increased breadth in cross-reactivity is due to an increase in
the avidity of antibodies that bind neutralizing epitopes that
are similar but not identical among the different species of
hantaviruses. As yet, we have not attempted to identify
neutralizing epitopes or measure the avidity of the antibodies
contained in the polyclonal immune serum generated by these
DNA vaccines. Others have reported that acute-phase serum
from HPS patients has an increased capacity to cross-
neutralize (Ye et al., 2004). The observation that a long-range
booster vaccination increases the breath of cross-neutralizing
activity suggests that future vaccination protocols involving
hantavirus M gene-based technologies should consider long-range boost components to raise the levels of neutralizing and
cross-neutralizing antibodies and to extend the duration of
immunity.
Species specificity
The HTNV and SEOV M gene-based DNA vaccines were
immunogenic in both hamsters and NHPs; however, the
ANDV M gene-based DNA vaccine and pWRG/HA-M were
immunogenic in NHPs but, inexplicably, not in hamsters. The
ANDV glycoproteins apparently have a dominant negative
effect on the immunogenicity of the HTNV glycoproteins
when they are combined on the same plamid because
hamsters vaccinated with this plasmid did not develop
neutralizing antibodies to HTNV. This effect could be due
to interactions between the recombinant HTNV and ANDV
glycoproteins (e.g., hetero-oligomers) that render the com-
plexes invisible to the hamster immune system. For example,
hetero-oligomers might be improperly targeted and/or rapidly
degraded before being presented to the hamster immune
system. The capacity of glycoproteins from heterologous
hantaviruses to interact when co-expressed in the same cells
has been reported previously (Deyde et al., 2005). Alterna-
tively, the ANDV glycoproteins might somehow down-
regulate the hamster’s immune response to the expressed
glycoproteins, and collaterally down-regulate the response to
the co-expressed HTNV glycoproteins. Hamsters infected
with ANDV develop HPS and succumb after approximately
10–12 days postchallenge but survivors do produce ANDV-
specific neutralizing antibodies indicating that hamsters can
develop anti-ANDV neutralizing antibodies under the appro-
priate conditions (Hooper et al., 2001b). It is tempting to
speculate that the inability of pWRG/AND-M or pWRG/
HA-M to elicit neutralizing antibodies is related to the
exceedingly high virulence of ANDV in hamsters. For example,
the ANDV glycoproteins could function to down-regulate the
immune response in hamsters, and this delay could then allow
dissemination of the virus with fatal consequences. At this point
in time, however, we have no evidence supporting such a
relationship, and the two phenomena could be completely
unrelated.
In summary, we demonstrated that it is possible to elicit
neutralizing antibody responses against both HFRS and HPS
hantaviruses using a single plasmid, dual-immunogen, DNA
vaccine administered by gene gun. In addition, we demon-
strated that hantavirus M gene-based DNA vaccines elicited
potent immunological memory and extraordinarily high levels
of neutralizing antibodies were rapidly produced after a single
long-range booster vaccination. The production-associated
benefits of combining multiple immunogens into a single
plasmid might be out-weighed by a loss in overall potency.
Here, we elicit neutralizing antibody titers that were 8- to 32-
fold lower in the dual-immunogen plasmids than in the single-
immunogen plasmids, albeit the number of vaccinated animals
was very low. Future investigations will include experiments to
determine if vaccination with a combination of single-
immunogen hantavirus M gene-based plasmids can elicit
J.W. Hooper et al. / Virology 347 (2006) 208–216 215neutralizing and cross-neutralizing antibody responses greater
than those achieved with pWRG/HA-M.
Materials and methods
Viruses, cells, and antibodies
HTNV, strain 76–118 (Lee et al., 1978), SEOV, strain SR-ll
(Kitamura et al., 1983), DOBV (Avsic-Zupanc et al., 1992),
PUUV, strain K27 (Tkachenko et al., 1984), ANDV strain
Chile-9717869 (Hooper et al., 2001b), BCCV (Rollin et al.,
1995), and SNV strain CC107 (Schmaljohn et al., 1995) were
propagated in Vero E6 cells (Vero C1008; ATCC CRL 1586).
Transient expression experiments were performed with COS-7
cells (COS-7; ATTC CRL1651). Both cell types were main-
tained in Eagle’s minimal essential medium with Earle’s salts
(EMEM) containing 10% fetal bovine serum (FBS), 10 mM
HEPES pH 7.4, and antibiotics (penicillin [100 U/ml],
streptomycin [100 Ag/ml], and gentamicin sulfate [50 Ag/ml])
(cEMEM) at 37 -C in a 5% CO2 incubator.
Immunoprecipitation
Radio-immunoprecipitation experiments were performed
using the HTNV G2-specific monoclonal antibody (MAb)-
HC02 (provided by Dr. J. McCormick of the Centers for
Disease Control, Atlanta, GA), the HTNV G1-specific MAb-
6D4, hyperimmune mouse ascetic fluid (HMAF) generated to
HTNV (Wang et al., 1993), or HPS convalescent phase sera
from Argentina, as described previously (Custer et al., 2003).
Construction of Hantaan/Andes dual M genome segment-based
DNA vaccine plasmid
Construction of the HTNV M DNA vaccine plasmid,
pWRG/HTN-M(x), and ANDV M DNA vaccine plasmid,
pWRG/AND-M, was described previously (Custer et al., 2003;
Hooper et al., 2001a). To construct a plasmid expressing both
the HTNV and ANDV glycoproteins, a fragment from pWRG/
AND-M containing the CMV promoter, intron A, ANDV M
genome segment, and bovine growth hormone polyadenylation
signal was PCR-amplified by using the following primers:
forward primer [5V-GGC CTC TAG AGC AGG TCG ACA
ATA TTG GCT ATT GGC C] and reverse primer [5V-GCG
CAA TTC TAG AGT CGA GCT GTC GAG CCC C]. Both
primers included an XbaI restriction site. The PCR reactions
were performed with Platinum Taq High Fidelity DNA
polymerase (Invitrogen, Carlsbad, CA): one 3-min cycle at
94 -C followed by 30 cycles of 94 -C 30 s, 68 -C 8 min. The
PCR product was cut with XbaI and then ligated into the XbaI
site of pWRG/HTN-M(x) using T4 DNA ligase (New England
Biolabs, Beverly, MA). The resulting dual-immunogen plas-
mid was designated pWRG/Hantaan/Andes-M (19a), or
pWRG/HA-M. Plasmid DNA was purified using Qiagen
maxiprep DNA purification kits according to the manu-
facturer’s directions. To confirm the identity of the new
construct, the HTNV and ANDV M genes contained inpWRG/HA-M were sequenced using an ABI 3100 genetic
analyzer.
Immunoprecipitation
Radio-immunoprecipitation assays (RIPA) using COS cell
lysate labeled with Promix ([35S]-methionine and [35S]-
cysteine, Amersham, Piscataway, NJ) were performed essen-
tially as described previously (Hooper et al., 2001a). Protein G-
Sepharose (Sigma, St. Louis, MO) was used in place of protein
A. Reduced samples were run on 4 to 12% gradient Tris–Bis
Nupage Gels using 1 MOPS as a running buffer with 1
MOPS-0.25% (vol/vol) antioxidant in the inner chamber, at
200 V constant voltage. Digital images were obtained using a
Cyclone phosphoimager (Packard, Meridan, CT).
Gene gun vaccinations
Cartridges for the gene gun were prepared as described
previously (Hooper et al., 1999, 2001a). Gene gun cartridges
consisting of 1 Ag of plasmid DNA coated on 0.5 mg of gold
were prepared and stored at 4 -C, desiccated, until use. Female
rhesus macaques (Macaca mulatta) were vaccinated with the
Powderject XR1 particle-mediated epidermal delivery device
(gene gun) (PowderMed, LTD), with four administrations at
nonoverlapping sites on the shaved abdomen and four over
inguinal lymph nodes using 400 lbs/inch2 of helium pressure.
Female Syrian hamsters (Mesocricetus auratus) more than
8 weeks old were vaccinated with the same type of cartridges
and the same gene gun conditions used to vaccinate the NHP;
however, the hamsters received four administrations (on
abdomen) per vaccination, rather than eight. Animals were
anesthetized during the nonpainful gene gun procedure. The
only visible effect was mild erythema at the vaccination sites.
Plaque-reduction neutralization tests (PRNT)
Neutralization assays were performed as previously de-
scribed (Hooper et al., 2001a). Serum samples were heat
inactivated and 5% guinea pig complement (Accurate Chem-
ical and Scientific Corp., Westbury, NY) was included in the
assay. HTNV, ANDV, SEOV, and BCCV PRNT were stained
with neutral red after 7 days; and PUUV, DOBV, and SNV
PRNT were stained after 10 days. Plates were incubated at
37 -C and plaques counted 2–3 days after staining.
N-specific ELISA
The enzyme-linked immunosorbent assay (ELISA) used to
detect antibodies that bind recombinant truncated hantavirus N
protein was described previously (Custer et al., 2003; Elgh et
al., 1997; Hooper et al., 1999).
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